Anti-Tumor Drugs Market Projected to Offer Substantial Growth Opportunities, Reaching $311.86 Billion by 2029
Grab 20% Off With Code ONLINE20 On Global market Reports – Evaluate Global Trends, Market Risks, and Competitive Intelligence
What Is the Comparative Market Size of the Anti-Tumor Drugs Market Between 2025 and 2029?
The anti-tumor drugs market size has grown rapidly in recent years. It will grow from $186.18 billion in 2024 to $206.81 billion in 2025 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to an increase in cancer incidence, growing adoption of targeted therapy and immunotherapy, an increase in clinical trials, a rise in personalized medicine approaches, and an increase in healthcare expenditure.
The anti-tumor drugs market size is expected to see rapid growth in the next few years. It will grow to $311.86 billion in 2029 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to growing focus on precision medicine, an increasing pipeline of novel anti-tumor agents, growing demand for oral oncology drugs, increasing penetration of anti-tumor drugs in emerging markets, and rising clinical trials for rare and refractory tumors. Major trends in the forecast period include developing bispecific antibodies for solid tumors, integrating genomic biomarkers in treatment planning, integrating companion diagnostics with drug launches, innovation in antibody-drug conjugates, and innovation in tumor microenvironment modulators.
Get your free report sample today:
What Are the Underlying Growth Drivers for the Anti-Tumor Drugs Market?
The increasing cancer incidence is expected to propel the growth of the anti-tumor drugs market going forward. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body, which can invade nearby tissues and potentially spread to other parts through the blood and lymph systems. The increasing cancer incidence is primarily due to unhealthy lifestyles, such as poor diet, lack of physical activity, smoking, excessive alcohol consumption, and prolonged exposure to environmental pollutants, which significantly raise the risk of developing various types of cancer. Anti-tumor drugs help combat cancer by targeting and destroying malignant cells, inhibiting tumor growth, and preventing disease progression. For instance, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2022, the number of cancer cases diagnosed in Australia reached 160,570, marking an increase of 3,789 cases compared to 156,781 in 2021. Therefore, the increasing cancer incidence is driving the growth of the anti-tumor drug market.
What Are the Major Segments Defining the Structure of the Anti-Tumor Drugs Market?
The anti-tumor drugs market covered in this report is segmented –
1) By Drug Type: Cytotoxic Drugs, Targeted Therapy Drugs, Hormonal Therapy Drugs, Immunotherapy Drugs, Other Drug Types
2) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Other Cancer Types
3) By Route of Administration: Oral, Injectable, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
Subsegments:
1) By Cytotoxic Drugs: Alkylating Agents, Antimetabolites, Plant Alkaloids, Antitumor Antibiotics, Other Cytotoxic Drugs
2) By Targeted Therapy Drugs: Monoclonal Antibodies, Tyrosine Kinase Inhibitors, Mechanistic Target Of Rapamycin Inhibitors, Poly Polymerase Inhibitors, Others Targeted Therapy Drugs
3) By Hormonal Therapy Drugs: Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Luteinizing Hormone-Releasing Hormone Agonists, Anti-Androgens, Other Hormonal Therapy Drugs
4) By Immunotherapy Drugs: Checkpoint Inhibitors, Chimeric Antigen Receptor T-Cell Therapy, Cancer Vaccines, Cytokines, Other Immunotherapy Drugs
5) By Other Drug Types: Gene Therapy Drugs, Anti-Angiogenic Agents, Radioisotope-Based Drugs, Photodynamic Therapy Agents
What New Market Trends Are Emerging in the Anti-Tumor Drugs Market?
Major companies operating in the anti-tumor drugs market are focusing on developing innovative therapies, such as targeted breast cancer treatment, to enhance therapeutic outcomes in hormone receptor-positive metastatic cases. Targeted breast cancer treatment involves precision therapies that specifically act on cancer cell growth pathways, minimizing damage to healthy cells and improving patient tolerance. For instance, in January 2023, Sun Pharmaceutical Industries Ltd., an India-based pharmaceutical company, launched Palbociclib, a novel anti-cancer drug for the treatment of advanced breast cancer in India. Palbociclib is a highly selective oral inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which play a key role in regulating cell cycle progression. By blocking the transition from the G1 to S phase, the drug induces cell cycle arrest, thereby inhibiting tumor growth. It is primarily indicated for hormone receptor-positive, HER2-negative advanced breast cancer, targeting the uncontrolled proliferation of cancer cells.
Which Firms Represent the Competitive Benchmark Within the Anti-Tumor Drugs Market?
Major companies operating in the anti-tumor drugs market are Pfizer Inc, Johnson And Johnson, Roche Holding AG, Merck And Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG., GlaxoSmithKline plc, Eli Lilly And Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim GmbH, Astellas Pharma Inc., Incyte Corporation, BeOne Medicines Inc., Getwell Oncology Pvt Ltd., Shanghai Haihe Pharmaceutical Co. Ltd.
Get the detailed anti-tumor drugs market report today
Which Regions Are Driving the Highest Demand in the Anti-Tumor Drugs Market?
North America was the largest region in the anti-tumor drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-tumor drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment